Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500
China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...
CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment
China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...
3SBio Acquires Licensing Rights to Duality Biologics’ HER2-Targeting ADC DB-1303
China-based 3SBio Inc. (HKG: 1530) has entered into a strategic partnership with Duality Biologics, a...
CBC Group’s R-Bridge Healthcare Fund Boosts Mirxes with $40M for Cancer Detection Expansion
CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in...
JW Therapeutics’ Carteyva Granted Breakthrough Therapy Designation by CDE
China-based JW Therapeutics (HKG: 2126) has announced that its Carteyva (relmacabtagene autoleucel injection) has been...
CSPC Pharmaceutical’s ADC Pipeline Advances with SYS 6041 Approval
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has reported significant progress in its antibody...
Suzhou Ribo and Boehringer Ingelheim Reach Pre-Clinical Milestone in NASH/MASH Partnership
China-based Suzhou Ribo Life Science Co., Ltd has announced the achievement of a first pre-clinical...
Johnson & Johnson MedTech’s Dual Energy Catheter Gains CE Mark
US major Johnson & Johnson MedTech has announced that its Dual Energy THERMOCOOL SMARTTOUCH SF...
Henlius Biotech Gains NMPA Clearance for HLX43 ADC Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that it has received clearance from...
Mabworks Biotech Licenses Anti-APRIL mAb to Climb Bio for Global Development
China-based Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070) has entered into a licensing deal...
Gilead Sciences and LEO Pharma Alliance Targets Inflammatory Diseases
US-based major Gilead Sciences Inc. (NASDAQ: GILD) has formed a strategic alliance with Denmark-based dermatology...
Junshi Biosciences’ Mindewei Receives Full Approval in China
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the conditional...
Ucello Biotech’s UC101 Receives FDA IND Clearance for Anti-CD19 Therapy
China-based Chengdu Ucello Biotechnology Co., Ltd., a developer of allogeneic universal chimeric antigen receptor (CAR)-T...
Harbour BioMed and Kelun Biotech License TSLP Monoclonal Antibody to Windward Bio
Chinese firms Harbour BioMed (HKG: 2142) and Sichuan Kelun Biotech BioPharmaceutical (HKG: 6990) have entered...
Hengrui’s Recaticimab Approved for Hypercholesterolemia Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its Category 1 biologic...
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica,...
Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1819 Phase II Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received the...
Hengrui Pharmaceuticals Receives NMPA Approval for SHR-4375 Clinical Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical...
Ouro Medicines Launches with $120M Series A Financing for CM336 Development
Ouro Medicines, the licensee of China-based Keymed Biosciences Inc.’s (HKG: 2162) CM336, has successfully launched...
Menarini Group Expands Oncology Pipeline with Insilico Medicine License
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal...